Judith R. Walters | |
|---|---|
 Walters in 2018 | |
| Alma mater | Mount Holyoke College Yale University |
| Scientific career | |
| Fields | Neurophysiological pharmacology |
| Institutions | National Institute of Neurological Disorders and Stroke |
| Doctoral advisor | Robert Henry Roth |
Judith Richmond Walters is an American neuropharmacologist serving as chief of the neurophysiological pharmacology section at the National Institute of Neurological Disorders and Stroke.
Walters received her B.A. degree from Mount Holyoke College and her Ph.D. from Yale University. [1] Her 1972 dissertation was titled Dopaminergic Neurons: Effect of Gamma-Hydroxybutyrate. [2] She studied the pharmacology and neurophysiology of the dopamine system in the basal ganglia. [3] Her doctoral advisor was Robert Henry Roth. [3] Walters did postdoctoral work at the department of psychiatry at the Yale University School of Medicine and then moved to the Experimental Therapeutics Branch in the National Institute of Neurological Disorders and Stroke (NINDS). [1]
Walters is a neuropharmacologist working as chief of the Neurophysiological Pharmacology Section at the NINDS. [1] Her laboratory explores the role of dopamine in basal ganglia-thalamocortical function. She studies the mechanisms in the brain that mediate dysfunctions associated with neurological diseases and disorders such as Parkinson’s disease. [1] She became a Fellow of the American Association for the Advancement of Science in 2018. [1] [4]
The substantia nigra (SN) is a basal ganglia structure located in the midbrain that plays an important role in reward and movement. Substantia nigra is Latin for "black substance", reflecting the fact that parts of the substantia nigra appear darker than neighboring areas due to high levels of neuromelanin in dopaminergic neurons. Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta.
Dopamine is a neuromodulatory molecule that plays several important roles in cells. It is an organic chemical of the catecholamine and phenethylamine families. Dopamine constitutes about 80% of the catecholamine content in the brain. It is an amine synthesized by removing a carboxyl group from a molecule of its precursor chemical, L-DOPA, which is synthesized in the brain and kidneys. Dopamine is also synthesized in plants and most animals. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons to send signals to other nerve cells. Neurotransmitters are synthesized in specific regions of the brain, but affect many regions systemically. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory.
The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the U.S. National Institutes of Health (NIH). It conducts and funds research on brain and nervous system disorders and has a budget of just over US$2.03 billion. The mission of NINDS is "to reduce the burden of neurological disease—a burden borne by every age group, every segment of society, and people all over the world". NINDS has established two major branches for research: an extramural branch that funds studies outside the NIH, and an intramural branch that funds research inside the NIH. Most of NINDS' budget goes to fund extramural research. NINDS' basic science research focuses on studies of the fundamental biology of the brain and nervous system, genetics, neurodegeneration, learning and memory, motor control, brain repair, and synapses. NINDS also funds clinical research related to diseases and disorders of the brain and nervous system, e.g. AIDS, Alzheimer's disease, epilepsy, muscular dystrophy, multiple sclerosis, Parkinson's disease, spinal cord injury, stroke, and traumatic brain injury.
Dopaminergic pathways in the human brain are involved in both physiological and behavioral processes including movement, cognition, executive functions, reward, motivation, and neuroendocrine control. Each pathway is a set of projection neurons, consisting of individual dopaminergic neurons.
The nigrostriatal pathway is a bilateral dopaminergic pathway in the brain that connects the substantia nigra pars compacta (SNc) in the midbrain with the dorsal striatum in the forebrain. It is one of the four major dopamine pathways in the brain, and is critical in the production of movement as part of a system called the basal ganglia motor loop. Dopaminergic neurons of this pathway release dopamine from axon terminals that synapse onto GABAergic medium spiny neurons (MSNs), also known as spiny projection neurons (SPNs), located in the striatum.
Hypokinesia is one of the classifications of movement disorders, and refers to decreased bodily movement. Hypokinesia is characterized by a partial or complete loss of muscle movement due to a disruption in the basal ganglia. Hypokinesia is a symptom of Parkinson's disease shown as muscle rigidity and an inability to produce movement. It is also associated with mental health disorders and prolonged inactivity due to illness, amongst other diseases.
The pars reticulata (SNpr) is a portion of the substantia nigra and is located lateral to the pars compacta. Most of the neurons that project out of the pars reticulata are inhibitory GABAergic neurons.
Pramipexole, sold under the brand Mirapex among others, is medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.
A neuromuscular disease is any disease affecting the peripheral nervous system (PNS), the neuromuscular junction, or skeletal muscle, all of which are components of the motor unit. Damage to any of these structures can cause muscle atrophy and weakness. Issues with sensation can also occur.
Ann Martin Graybiel is an Institute Professor and a faculty member in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology. She is also an investigator at the McGovern Institute for Brain Research. She is an expert on the basal ganglia and the neurophysiology of habit formation, implicit learning, and her work is relevant to Parkinson's disease, Huntington's disease, obsessive–compulsive disorder, substance abuse and other disorders that affect the basal ganglia.
Basal ganglia disease is a group of physical problems that occur when the group of nuclei in the brain known as the basal ganglia fail to properly suppress unwanted movements or to properly prime upper motor neuron circuits to initiate motor function. Research indicates that increased output of the basal ganglia inhibits thalamocortical projection neurons. Proper activation or deactivation of these neurons is an integral component for proper movement. If something causes too much basal ganglia output, then the ventral anterior (VA) and ventral lateral (VL) thalamocortical projection neurons become too inhibited, and one cannot initiate voluntary movement. These disorders are known as hypokinetic disorders. However, a disorder leading to abnormally low output of the basal ganglia leads to reduced inhibition, and thus excitation, of the thalamocortical projection neurons which synapse onto the cortex. This situation leads to an inability to suppress unwanted movements. These disorders are known as hyperkinetic disorders.
Avindra "Avi" Nath, is a physician-scientist who specializes in neuroimmunology. Nath is a senior investigator, and intramural clinical director of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) in the United States. At NINDS, Nath also leads the Section of Infections of the Nervous System and plans to institute a translational research center. He previously served in several research and administrative positions at the Johns Hopkins Hospital and the Johns Hopkins University School of Medicine.
Anne Buckingham Young is an American physician and neuroscientist who has made major contributions to the study of neurodegenerative diseases, with a focus on movement disorders like Huntington's disease and Parkinson's disease. Young completed her undergraduate studies at Vassar College and earned a dual MD/PhD from Johns Hopkins Medical School. She has held faculty positions at University of Michigan and Harvard University. She became the first female chief of service at Massachusetts General Hospital when she was appointed Chief of Neurology in 1991. She retired from this role and from clinical service in 2012. She is a member of many academic societies and has won numerous awards. Young is also the only person to have been president of both the international Society for Neuroscience and the American Neurological Association.
Gene therapy in Parkinson's disease consists of the creation of new cells that produce a specific neurotransmitter (dopamine), protect the neural system, or the modification of genes that are related to the disease. Then these cells are transplanted to a patient with the disease. There are different kinds of treatments that focus on reducing the symptoms of the disease but currently there is no cure.
Patricia A. Grady is an American neuroscientist internationally recognized for her research on stroke, which specializes in cerebral blood flow, metabolism, and function. She is director of the National Institute of Nursing Research (NINR), part of the National Institutes of Health (NIH) in Bethesda, Maryland. Grady was elected to the Institute of Medicine in 1999 and is a member of several scientific organizations, including the Society for Neuroscience and the American Academy of Nursing. She is a fellow of the American Stroke Association and the American Neurological Association.
Audrey Shields Penn is an American neurologist and emeritus professor. Her major area of research was in the biochemistry of muscle weakness in myasthenia gravis. Penn was elected President of the American Neurological Association in 1994. She was deputy director of the National Institute of Neurological Disorders and Stroke (NINDS), and is the first African-American woman to serve as an (acting) director of an Institute of the National Institutes of Health (NIH).
Rebecca Gottesman is Senior Investigator and Stroke Branch Chief at the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). Before joining NINDS, she was Professor of Neurology and Epidemiology at Johns Hopkins University. Gottesman completed a B.A. in Psychology at Columbia University (1995), an M.D. at Columbia University (2000), and a Ph.D. in Clinical Investigation at Johns Hopkins University (2007). She is a Fellow of the American Neurological Association (2012) and a Fellow of the American Heart Association (2015).
Emmeline Edwards is a Haitian-American neurochemist serving as director of the division of extramural research at the National Center for Complementary and Integrative Health. She previously researched the neural mechanisms of complex behaviors and characterization of a genetic model of affective disorders at the University of Maryland, College Park. From 2000 to 2010, Edwards was deputy director of the extramural program at the National Institute of Neurological Disorders and Stroke.
Nina Felice Schor is an American physician-scientist and pediatric neurologist. She has served as director of the NIH Intramural Research Program since the Fall of 2022. Schor was the deputy director of National Institute of Neurological Disorders and Stroke from 2018 to 2022. She was the William H. Eilinger Chair of the Department of Pediatrics at University of Rochester and Pediatrician-in-Chief of the Golisano Children’s Hospital from 2006 to January 2018.
Heather A. Cameron is an American neuroscientist who researches adult neurogenesis and diseases involving the hippocampus. She is the chief of the neuroplasticity section at the National Institute of Mental Health.
This article incorporates text from this source, which is in the public domain . This article incorporates text from this source, which is in the public domain . This article incorporates public domain material from websites or documents of the National Institutes of Health.| International | |
|---|---|
| National | |
| Academics | |
